BMS 502 |
| Catalog No.GC91140 |
Un inhibiteur de DGK-α, DGK-ζ et DGK-ι.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2407854-18-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BMS 502 is an inhibitor of diacylglycerol kinase α (DGK-α), DGK-ζ, and DGK-ι (IC50s = 0.0046, 0.0021, and 0.0026 µM, respectively).1 It is selective for these DGKs over DGK-β, DGK-γ, and DGK-κ (IC50s = 1, 0.68, and 4.6 µM, respectively). BMS 502 increases levels of IFN-γ and phosphorylation of ERK in isolated human whole blood (EC50s = 0.28 and 0.52 µM, respectively). It also increases the proliferation of CD8+ T cells (EC50 = 0.065 µM), which express DGK-α and DGK-ζ but not DGK-ι. BMS 502 (0.3-10 mg/kg) increases the frequency of CD69+CD8+ T cells when administered in combination with the peptide antigen SIINFEKL in OT I mice, which express modified murine T cell receptors that recognize SIINFEKL.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *